Skip to content
Open access

Lipid nanoparticle-mediated RNAi targeting of KRAS mutants sensitises colorectal cancer cells to chemotherapy

Oct 2026 · bioRxiv · 0 citations · 35 references
Biology

Abstract

KRAS mutations, including G12D, G12V and G13D, are major oncogenic drivers in colorectal cancer (CRC) and are associated with therapeutic resistance. However, approved KRAS inhibitors remain focused on G12C subtype, leaving these prevalent variants without approved targeted therapies. Here, we developed a lipid nanoparticle (LNP)-based RNA interference (RNAi) strategy to target these three KRAS variants using a single small interfering RNA (siRNA) sequence. The developed siRNA-LNPs reduced KRAS mRNA and protein expression in HCT116 (G13D), SW620 (G12V) and LS180 (G12D) cells, but not in KRAS wild-type HT29 cells, suppressing the cellular proliferation, clonogenic survival and migration. Transcriptomic profiling revealed changes in KRAS associated signalling, including suppression of cell-cycle and DNA repair programmes, providing a rationale for combining siRNA silencing with the fluoropyrimidine chemotherapeutic agent 5-fluorouracil (5-FU). The combination produced synergistic effects across all three KRAS-mutant CRC cell models and enhanced the apoptosis in both monolayer cultures and 3D spheroids. Collectively, these findings provide proof of concept for this combination strategy and support its further investigation as a potential therapeutic approach for KRAS-mutant CRC.

Read PDF

Similar papers

Open access Oct 2026

KRASG12D-targeted therapy sensitivity depends on interferon signaling activation in pancreatic cancer.

KRASG12D is a predominant driver in pancreatic cancer, yet the basis of intrinsic resistance to KRASG12D-targeted therapy remains poorly defined. Integrated genomics, transcriptomics, and proteomics profiling across 242 patient-derived organoids (PDOs) and matched tumor tissues reveals a KRASG12D-mutant subset intrinsi...

Ye-Han Zhang, Shi-Jie Tang, Yi Zhang et al. · 1 citation
Open access Oct 2026

Targeting adaptive EGFR feedback enhances the therapeutic efficacy of RMC-6236 in cholangiocarcinoma

Approximately 20% of cholangiocarcinomas harbor KRAS mutations, with codon 12 variants accounting for most of the cases. Among these, G12V is associated with a poor prognosis, whereas G12D is the most frequent subtype. RMC-6236, a novel RAS (ON) multi-selective inhibitor targeting multiple KRAS codon 12 mutations, has...

S. Yamazaki, N. Hondo, K. Yasukawa et al. · 0 citations
Review Sep 2026

Targeting KRAS-Mutant Lung Cancers.

KRAS biology, therapeutic advances, mechanisms of resistance, and emerging strategies that are reshaping the treatment landscape of KRAS-mutant NSCLC are comprehensively summarized.

E. Garbo, P. Scaparone, H. J. Hoe et al. · 0 citations
#gene editing Review Oct 2026

Progress in polymeric nanoparticle-based treatment approaches for Wnt β-catenin pathway modulation and adenomatous polyposis coli mutant colorectal cancer.

About 80-90% of sporadic instances of colorectal cancer (CRC) are caused by mutations in the adenomatous polyposis coli (APC) gene, which is one of the earliest and most common molecular events. The constitutive activation of the Wnt/β-catenin signalling pathway caused by APC dysfunction promotes unchecked cellular pro...

Tanvi Maheshwari, Sankha Bhattacharya, Dilpreet Singh · 0 citations
Review Open access Sep 2026

Molecular landscape of KRAS G12C inhibitor resistance and rational combination strategies in cancer therapy

Background: Oncogenic alterations in KRAS are among the most frequent driver mutations in human cancers, particularly lung, colorectal, and pancreatic cancers. Mutant KRAS was historically considered an “undruggable” target because of its high affinity for guanosine triphosphate and guanosine diphosphate (GDP) and the...

V. Adhao, Sakshi N. Patil · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.